Stephan Jackman
Chief Executive Officer en ALZAMEND NEURO, INC. .
Fortuna: 3 033 $ al 31/03/2024
Perfil
Stephan Jackman is currently the Chief Executive Officer & Director at Alzamend Neuro, Inc. He previously served as the Chief Operating Officer at Ennaid Therapeutics LLC from 2015 to 2017 and at Exit 9 Technologies, Inc. from 2017 to 2018.
Mr. Jackman received his undergraduate and graduate degrees from Stevens Institute of Technology.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ALZAMEND NEURO, INC.
0.04% | 24/08/2023 | 3 033 ( 0.04% ) | 3 033 $ | 31/03/2024 |
Cargos activos de Stephan Jackman
| Empresas | Cargo | Inicio |
|---|---|---|
| ALZAMEND NEURO, INC. | Chief Executive Officer | 20/11/2018 |
Antiguos cargos conocidos de Stephan Jackman.
| Empresas | Cargo | Fin |
|---|---|---|
| Exit 9 Technologies, Inc. | Chief Operating Officer | 01/11/2018 |
Ennaid Therapeutics LLC
 Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Chief Operating Officer | 01/10/2017 |
Formación de Stephan Jackman.
| Stevens Institute of Technology | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
| Alzamend Neuro, Inc. | |
Ennaid Therapeutics LLC
Ennaid Therapeutics LLC BiotechnologyHealth Technology Ennaid Therapeutics LLC develops orally deliverable anti-viral peptide that treats and prevents Zika virus. The company was founded by Darnisha Grant Harrison in 2012 and is headquartered in Alpharetta, GA. | Health Technology |
| Exit 9 Technologies, Inc. |
- Bolsa de valores
- Insiders
- Stephan Jackman
